Aveanna Healthcare Holdings Inc (AVAH) concluded trading on Thursday at a closing price of $5.14, with 3.4 million shares of worth about $17.46 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 2.19% during that period and on March 13, 2025 the price saw a gain of about 37.43%. Currently the company’s common shares owned by public are about 193.23M shares, out of which, 54.59M shares are available for trading.
Stock saw a price change of 34.91% in past 5 days and over the past one month there was a price change of 4.47%. Year-to-date (YTD), AVAH shares are showing a performance of 12.47% which increased to 118.72% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.11 but also hit the highest price of $6.19 during that period. The average intraday trading volume for Aveanna Healthcare Holdings Inc shares is 196.37K. The stock is currently trading 19.85% above its 20-day simple moving average (SMA20), while that difference is up 13.19% for SMA50 and it goes to 14.61% higher than SMA200.
Aveanna Healthcare Holdings Inc (NASDAQ: AVAH) currently have 193.23M outstanding shares and institutions hold larger chunk of about 22.47% of that.
The stock has a current market capitalization of $993.17M and its 3Y-monthly beta is at 2.24. It has posted earnings per share of -$0.34 in the same period. It has Quick Ratio of 0.94. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AVAH, volatility over the week remained 8.04% while standing at 7.08% over the month.
Stock’s fiscal year EPS is expected to rise by 36.67% while it is estimated to increase by 98.17% in next year. EPS is likely to grow at an annualized rate of 65.10% for next 5-years, compared to annual growth of -22.80% made by the stock over the past 5-years.
Coverage by UBS stated Aveanna Healthcare Holdings Inc (AVAH) stock as a Sell in their note to investors on November 30, 2023, suggesting a price target of $1.50 for the stock. On May 12, 2023, Raymond James Downgrade their recommendations, while on January 27, 2023, Credit Suisse Downgrade their ratings for the stock with a price target of $1. Stock get a Sector perform rating from RBC Capital Mkts on November 21, 2022.
